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Gallbladder cancer (GBC) has an extremely poor prognosis.
Resection for cure has been reported to be possible in only
20–40% of cases, and 5-year survival rates following such resec-
tion have ranged from 5–40% (Ogura et al, 1991; Bartlett et al,
1996; Benoist et al, 1998). Recent advances in hepatobiliary
imaging, introduction of extended operations combining liver
resection with wide lymph node dissection, and increases in inci-
dental histologic diagnosis of early-stage cancer following laparo-
scopic cholecystectomy are beginning to improve the prognosis of
GBC (Bartlett et al, 1996; Shimada et al, 1997). As another result,
new controversies have emerged in the surgical management of
GBC, especially concerning the incidentally discovered cases.
Specifically, questions persist as to whether reoperation to achieve
wider resection is indicated when tumours are discovered inciden-
tally at histologic examination after simple cholecystectomy. More
complete information for planning therapeutic strategies and for
developing therapy is needed to further improve clinical outcome.
This need includes a better understanding of the molecular basis of
gallbladder carcinogenesis and identification of prognostically
important biologic markers. 
A mouse monoclonal antibody designated 22-1-1 was produced
against a human uterine adenocarcinoma cell line, SiSo, in 1996
(Sonoda et al, 1995; Sonoda et al, 1996). A cDNA encoding the
antigen recognized by the 22-1-1 antibody was termed ‘receptor
binding cancer antigen expressed on SiSo cells’, or RCAS1.
Cancers escape immune surveillance by a variety of mechanisms,
including some evasive strategies to avoid immune recognition, but
also active modulation and suppression of immune cell function. The
RCAS1 gene product is a membrane constituent that acts as a ligand
for a putative receptor present on various human cells including
normal peripheral lymphocytes such as T, B, and natural killer cells.
RCAS1 inhibited growth of receptor-expressing cells in vitro and
induced apoptotic cell death. Given these results, tumour cells could
evade immune surveillance by expression of RCAS1, which would
act to suppress clonal expansion and induce apoptosis in immune
cells possessing RCAS1 receptors (Nakashima et al, 1999). 
In uterine, ovarian and lung cancer, RCAS1 expression has been
associated with a poorer prognosis in those cancers (Sonoda et al,
1996; Kaku et al, 1999; Iwasaki et al, 2000). Whether expression
of this antigen is related to carcinogenesis, tumour progression,
and prognosis in other organs is not known. 
To elucidate the role of RCAS1 in carcinogenesis and tumour
progression in GBC, we immunohistochemically investigated
RCAS1 expression in 110 surgically resected gallbladder speci-
mens, including pre-cancerous as well as cancerous lesions. In
case of cancer, we analysed the relationship between RCAS1
immunopositivity and clinical and histopathologic features. 
RCAS1 as a tumour progression marker: an independent
negative prognostic factor in gallbladder cancer 
T Oshikiri1, Y Hida1, M Miyamoto1, H Hashida1, K Katoh1, M Suzuoki1, Y Nakakubo1, K Hiraoka1, T Shinohara2, T Itoh3,
S Kondo1 and H Katoh1
1Department of Surgical Oncology, Division of Cancer Medicine, Hokkaido University Graduate School of Medicine, North 15, West 7, Kita-ku, Sapporo, 
060-8638, Japan; 2Department of Pathology, Teinekeijinkai Hospital, 1–12, Maeda, Teine-ku, Sapporo, 006–0811, Japan; 3Department of Surgical Pathology,
Hokkaido University Hospital, North 15, West 7, Kita-ku, Sapporo, 060-8638, Japan 
Summary Receptor-binding cancer antigen expressed on SiSo cells (RCAS1) induces apoptosis in immune cells bearing the RCAS1
receptor. We sought to determine RCAS1 involvement in the origin and progression of gallbladder cancer, and also implications of RCAS1
for patient survival. RCAS1 expression was examined immunohistochemically in 110 surgically resected gallbladder specimens. The
gallbladders represented 20 cases of cholecystitis with no associated pancreaticobiliary maljunction; 23 cases of cholecystitis with
pancreaticobiliary maljunction; 14 cases of adenomyomatosis; 7 adenomas; and 46 cancers. High expression of RCAS1 (immunoreactivity in
over 25% of cells) was observed in 32 of the 46 cancers (70%), but not in other diseases, including pre-cancerous conditions. RCAS1
immunoreactivity was associated with depth of tumour invasion (P = 0.0180), lymph node metastasis (P = 0.0033), lymphatic involvement 
(P = 0.0104), venous involvement (P = 0.0224), perineural involvement (P = 0.0351) and stage by the tumour, nodes and metastases (TNM)
classification (P = 0.0026). Thus, RCAS1 expression may be a relatively late event in gallbladder carcinogenesis, possibly promoting tumour
progression. Cox regression multivariate analysis demonstrated RCAS1 positivity to be an independent negative predictor for survival 
(P = 0.0337; risk ratio, 12.690; 95% confidence interval, 1.216–132.423). High expression of RCAS1 significantly correlated with tumour
progression and predicted poor outcome in gallbladder cancer. © 2001 Cancer Research Campaign http://www.bjcancer.com
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MATERIAL AND METHODS 
Patients and tissue specimens 
Between 1989 and 1999, a total of 110 gallbladders were resected
in the Second Department of Surgery at the Hokkaido University
School of Medicine and the Departments of Surgery at Hokkaido
Gastroenterology Hospital and Teinekeijinkai Hospital. Gallbladder
specimens included seven adenomas, 14 cases of adenomyomatosis,
23 cases of cholecystitis associated with pancreaticobiliary maljunc-
tion (PBM), 20 cases of cholecystitis without PBM, and 46 carci-
nomas. Among the seven gallbladder adenomas six were tubular
and 1 was papillary. The ages of patients with cancer ranged from
32–86 years (median 67); 17 patients were men and 29 were
women. Patients were grouped according to age as being either
< or ≥ 67 years old. The clinicopathologic features of these cases
were used to evaluate the lesion according to the pathologic
tumour node and metastases (pTNM) classification of the
International Union Against Cancer (Sobin et al, 1997). Among all
46 patients, 42 had systematic follow-up examinations. The
median duration of follow-up was 41.0 months (range 3.1–40.8
months). 
Immunohistochemistry 
Surgical specimens were fixed in 10% formalin solution and
embedded by routine methods in paraffin for sectioning at a thick-
ness of 4 µ m. Sections were then deparaffinized in xylene and
rehydrated through a graded ethanol series. Endogenous peroxidase
was blocked with 3% hydrogen peroxide for 10 min. Sections then
were washed twice in phosphate-buffered saline (PBS) and incubated
with 10% normal goat serum (Histofine SAB-PO kit; Nichirei,
Tokyo, Japan) for 30 min. Primary antibody (anti-RCAS1 mouse
monoclonal antibody, Medical & Biological Laboratories, Tokyo,
Japan) was applied in a 1:500 dilution in PBS, and the sections were
incubated overnight at 4˚C. After 3 additional washes, sections were
incubated with polyvalent biotinylated goat anti-mouse antibody for
30 min at room temperature. Sections were washed 3 times in PBS
and incubated with streptavidin-conjugated peroxidase for 30 min.
After 3 additional washes, reaction product was visualized by incu-
bation with 3,3′ -diaminobenzidine tetrahydrochloride (Histofine
SAB-PO kit; Nichirei Tokyo, Japan) for approximately 15 min,
followed by washing in distilled water. Sections then were counter-
stained in haematoxylin for 1 min and mounted in Permount. As a
positive control, sections of a uterine adenocarcinoma previously
found to express the RCAS1 protein were affixed to the same slides
as the gallbladder sections and were stained in parallel. In a negative
control, non-immune purified mouse IgM was substituted for the
primary antibody.
Evaluation of immunoreactivity 
The degree of RCAS1 immunoreactivity was used to classify
cases into four categories according to widely used criteria (Loda
et al, 1997; Porter et al, 1997; Anayama et al, 1998). In RCAS1 I
cases, fewer than 25% of tumour cells showed immunoreactivity;
in RCAS1 II, 25–50%; in RCAS1 III, 50–75%; and in RCAS1 IV,
more than 75%. RCAS1 II, III, and IV were considered high-
expression patterns, while RCAS1 I was considered to be low
expression. Scoring of RCAS1 immunoreactivity was based on
examination of 10 high-power (× 400) microscopic fields equiva-
lent to 1000 cells for each section. Immunoreactivity in each
section was reviewed by each of three investigators. In cases of
occasional discrepancy in the interpretation, consensus was
achieved after discussion with the aid of a multiheaded micro-
scope. 
Statistical analysis 
The χ 2 test or Fisher’s test was used as appropriate to evaluate the
significance of RCAS1 status with respect to various clinicopatho-
logic parameters. The Kaplan–Meier method was used to estimate
overall survival. Survival differences according to RCAS1 expres-
sion were analyzed by the log rank test. The influence of variables
on survival was assessed using Cox univariate and multivariate
regression analyses. Probability values of less than 0.05 were
regarded as indicating significance. 
RESULTS 
RCAS1 expression in cases of cholecystitis,
adenomyomatosis and adenoma 
RCAS1 immunoreactivity was present in less than 5% of cells in
all 20 cases of cholecystitis without PBM (Figure 1A), all 14
cases of adenomyomatosis (Figure 1B), all 23 cases of cholecys-
titis with PBM (Figure 1C), and in all 7 cases of adenomas
(Figure 1D). 
RCAS1 expression in GBC 
A total of 46 GBCs were grouped as 14 RCAS1 I tumours (30%;
Figure 1E); 7 RCAS1 II tumours (15%; Figure 1F); 10 RCAS1 III
tumours (22%; Figure 1G); and 15 RCAS1 IV tumours (33%;
Figure 1H). Thus, 32 tumours (70%) were classified as showing
high RCAS1 expression (more than 25% of cells). 
The frequency of high RCAS1 expression increased with
tumour stage according to the pTNM system: 44.4% of stage I (4
of a total of 9 cases), 53.3% of stage II (8 of a total of 15 cases),
85.7% of stage III (6 of a total of 7 cases), and 93.3% of stage IV
(14 of a total of 15 cases; Table 1). RCAS1 immunoreactivity
showed a significant relationship to depth of tumour invasion
(P= 0.0180), lymph node metastasis (P= 0.0033), lymphatic involve-
ment (P = 0.0104), venous involvement (P = 0.0224), perineural
involvement (P = 0.0351), and pTNM stage (P = 0.0026) by the χ 2
test. No significant association was noted between RCAS1 expres-
sion and other clinicopathologic features (Table 2). 
Kaplan–Meier survival analysis 
Survival curves constructed according to the Kaplan–Meier
method are shown in Figures 2 and 3. In 42 patients with GBC,
survival in patients with a high RCAS1 expression pattern was
Table 1 RCAS1 expression in GBCs by tumour stage 
Histopathologic stagea No. of cases No. of positive cases 
I 9 4 (44.4%) 
II 15 8 (53.3%) 
III 7 6 (85.7%) 
IV 15 14 (93.3%) 
aStaging was carried out by the pTNM system. 1924 T Oshikiri et al
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Figure 1 Representative examples of RCAS1 immunohistochemistry. RCAS1 immunoreactivity was observed in less than 5% of cells of (A) cases of
cholecystitis without pancreaticobiliary maljunction (PBM), (B) cholecystitis with PBM, (C) adenomyomatosis, and (D) adenoma. In cancer cells, RCAS1
was demonstrated both in the cytoplasm and on the cell membrane. Cancers were classified as (E) RCAS1 I (less than 25% of cells stained), (F) RCAS1 II
(25–50% of cells stained), (G) RCAS1 III (50–75% of cells stained), or (H) RCAS1 IV (more than 75% of cells stained). (Original magnification (A, B, D) × 200,
(C, E, F, G, H] × 400) RCAS1 in gallbladder cancer 1925
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significantly worse than in those with a low-expression pattern (log
rank test, P = 0.0001; Figure 2). A similar tendency was noted in 21
patients with pT2 cancer (log rank test, P = 0.0074; Figure 3). 
Univariate survival analysis 
Univariate analysis performed by Cox regression identified age
(P = 0.0064), histologic tumour type (P = 0.0036), depth of
tumour invasion (P < 0.0001), lymph node metastasis (P < 0.0001),
lymphatic involvement (P = 0.0010), venous involvement 
(P = 0.0001), perineural involvement (P = 0.0003), and RCAS1
positivity (P = 0.0047) as showing significant correlation with
survival in 42 patients with GBC (Table 3). For 21 patients with
pT2 cancer, only RCAS1 positivity (P = 0.0257) was associated
with a significant difference in patient survival (Table 4). 
Multivariate survival analysis 
Factors that showed a significant difference in patient survival by
univariate survival analysis were considered further in a multi-
variate survival analysis. Cox regression multivariate analysis indi-
cated that depth of tumour invasion (P = 0.0175), lymph node
Table 2 Association of RCAS1 expression with selected clinicopathologic
characteristics in patients with GBC 
Variable RCAS1 expression P-valuea
Positive (%) Negative (%) 
Patients (n) 32 (70) 14 (30) 
Age (years) 0.2767 
< 67 17 (77) 5 (23) 
≥ 67 15 (63) 9 (37) 
Sex 0.2254 
Male 10 (59) 7 (41) 
Female 22 (76) 7 (24) 
Histologic type 0.1037 
Papillary/well 17 (61) 11 (39) 
Moderately/poorly 15 (83) 3 (17) 
Depth of tumour invasion 0.0180 
Tis, T1, T2 18 (58) 13 (42) 
T3, T4 14 (93) 1 (  7) 
Lymph node metastasis 0.0033 
Negative 15 (54) 13 (46) 
Positive 17 (94) 1 (  6) 
Lymphatic involvement 0.0104 
Negative 12 (52) 11 (48) 
Positive 20 (87) 3 (13) 
Venous involvement 0.0224 
Negative 16 (57) 12 (43) 
Positive 16 (89) 2 (11) 
Perineural involvement 0.0351 
Negative 17 (59) 12 (41) 
Positive 15 (88) 2 (12) 
Stage by TNMb 0.0026 
Stage I or II 12 (50) 12 (50) 
Stage III or IV 20 (91) 2 (  9) 
aFrom the χ 2 test. bTNM: tumour, nodes and metastases; is: in situ. 
Table 3 Evaluation of possible prognostic factors including RCAS1 expression in 42 patients with GBC using Cox regression
analysis 
Variables Univariate analysis Multivariate analysis 
Risk ratio 95% CI P-value Risk ratio 95% CI P-value 
Age (≥ 67/< 67) 3.874 1.462–10.263 0.0064 2.117 0.576–7.789 0.2589 
Sex (F/M) 1.299 0.526–3.207 0.5699 
Histologic type 4.074 1.582–10.489 0.0036 0.266 0.030–2.364 0.2348 
Pap and well/mod and poor) 
Depth of tumor invasion 12.230 4.390–34.072 < 0.0001 13.179 1.571–110.575 0.0175 
(Tis, T1, T2/T3, T4) 
Lymph node metastasis 11.019 4.032–30.114 < 0.0001 4.918 1.127–21.459 0.0341 
(Negative/positive) 
Lymphatic involvement 5.195 1.940–13.991 0.0010 4.048 0.931–17.592 0.0621 
(Negative/positive) 
Venous involvement 6.726 2.564–17.644 0.0001 1.784 0.194–16.371 0.6088 
(Negative/positive) 
Peri-neural involvement 5.526 2.173–14.056 0.0003 0.418 0.056–3.102 0.3948 
(Negative/positive) 
RCAS1 (–/+) 18.763 2.456–143.367 0.0047 12.690 1.216–132.423 0.0337 
Pap: papillary adenocarcinoma; well: well-differentiated adenocarcinoma; Mod: moderately differentiated adenocarcinoma; poor:
poorly differentiated adenocarcinoma; is: in situ.
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Figure 2 Kaplan–Meier curves for overall survival according to RCAS1
expression (high expression vs low expression, compared using the log rank
test) in 42 patients who underwent radical surgery for gallbladder cancer1926 T Oshikiri et al
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metastasis (P = 0.0341), and RCAS1 positivity (P = 0.0337) were
independent unfavourable factors in 42 patients with GBC (Table 3). 
DISCUSSION 
The present study showed that: 
1. Occurrence of high RCAS1 expression increases as tumour
stage advances 
2. High RCAS1 expression is related to depth of tumour invasion,
lymph node metastasis, and invasion of lymphatics, veins, and
perineural areas 
3. High RCAS1 expression is an independent unfavourable prog-
nostic factor. 
We investigated various gallbladder lesions, some considered
pre-cancerous, in order to evaluate possible involvement of
RCAS1 in carcinogenesis. Conditions examined included PBM,
adenomyomatosis, and adenoma. The incidence of biliary cancer
in patients with PBM has been reported as 23.6–37.3% (Aoki et al,
1987; Uchimura et al, 1991). On the other hand, adenomyomatosis
of the gallbladder is generally considered to carry no risk of malig-
nant transformation, although a few cases have been reported
where adenocarcinoma was associated with adenomyomatosis
(Katoh et al, 1988; Ootani et al, 1992). Adenoma has been charac-
terized as a precursor of GBC (Kozuka et al, 1982). We immunos-
tained sections of pre-cancerous lesions together with sections
from positive control specimens affixed to the same glass slides to
minimize the chance of a false-negative result. In these cases, only
the control section showed strong RCAS1 immunoreactivity.
Cancer-specific genes that have been relatively well investigated
in GBC include p53 and K-ras. Mutations at these loci are consid-
ered to be early events in gallbladder carcinogenesis, being likely
to participate in transforming pre-cancerous lesions to cancer but
unlikely to influence the clinical properties of GBC (Ajiki et al,
1996a, 1996b). In our immunohistochemical study, high expres-
sion of RCAS1 was observed frequently in GBC (70%), but was
never seen in pre-cancerous lesions. This suggests that RCAS1 is
probably not involved in the origins of GBC. Instead, RCAS1
appears to be a late event, which means tumour progression and
not malignant transformation, as a part of a multistep process of
gallbladder carcinogenesis. 
Strong expression of RCAS1 by GBC was significantly associ-
ated with depth of tumour invasion, lymph node metastasis,
lymphatic involvement, venous involvement, and peri-neural
involvement. An association between RCAS1 expression and
depth of tumour invasion has been reported for non-small cell lung
cancer (Iwasaki et al, 2000). Iwasaki et al reported more frequent
occurrence of apoptosis in tumour-infiltrating lymphocytes in lung
cancers strongly expressing RCAS1 than in lung cancers showing
less expression. One possible explanation for those findings is that
GBC cells expressing RCAS1 may escape immune surveillance
and survive in lymphatic vessels, lymph nodes, and the extracel-
lular matrix. In addition, RCAS1-expressing cells may have a
survival advantage over tumour cells not expressing the protein, so
cells expressing RCAS1 would constitute an increasing fraction of
tumour cells as invasion deepened. As a tumour penetrates more
deeply, it is more likely to make contact with lymphatic, venous,
and peri-neural structures in the submucosal layer. Expression of
RCAS1, then, would be expected to correlate with involvement of
these structures. 
For patients who have undergone cholecystectomy with a subse-
quent incidental finding of gallbladder cancer in the resected spec-
imen, radical re-operation may be necessary if the tumour has
extended into peri-muscular connective tissue (T2) and expresses
RCAS1. In particular, a patient whose tumour shows high RCAS1
expression may be a candidate for extended resection including
lymph node dissection, since lymph node metastasis is likely. 
A particularly important finding is that RCAS1 expression was
associated with a short period of survival in patients who have had
a resectable GBC. Cox regression univariate analysis showed high
expression of RCAS1 to be the prognostic factor among pT2
cancers. Surgical resection failed to cure the patients with GBC
showing high expression of RCAS1 protein, and advanced cancer
with such expression requires aggressive therapy. As new therapeutic
strategies, targeting of tumours using antibodies against cancer
specific antigens may be candidate. Several studies of radio-
immunotherapy using radiolabelled anti-carcinoembryonic antigen
(CEA) or anti-CD22 have been reported (Casey et al, 1999; Linden
et al, 1999). Our data suggested that RCAS1 could be a potential
target for GBC radioimmunotherapy. 
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Figure 3 Kaplan–Meier curves for overall survival according to RCAS1
expression (high expression vs low expression, compared using the log rank
test) in 21 patients with pT2 gallbladder cancer 
Table 4 Prognostic value of RCAS1 expression and other variables in 21
patients with pT2 GBC using Cox regression analysis 
Variables Univariate analysis 
Risk ratio 95% CI P-value 
Age (≥ 67/< 67) 3.269 0.724–14.750 0.1234 
Sex (F/M) 1.723 0.383–7.750 0.4781 
Histologic type 1.950 0.431–8.832 0.3861 
(Pap and well/mod and poor) 
Lymph node metastasis 4.287 0.951–19.320 0.0580 
(Negative/positive) 
Lymphatic involvement 2.822 0.614–12.969 0.1824 
(Negative/positive) 
Venous involvement 1.612 0.311–8.349 0.5691 
(Negative/positive) 
Peri-neural involvement 0.684 0.082–5.696 0.7252 
(Negative/positive) 
RCAS1 (–/+) 12.560 1.360–115.990 0.0257 
Pap: papillary adenocarcinoma; well: well-differentiated adenocarcinoma;
Mod: moderately differentiated adenocarcinoma; poor: poorly differentiated
adenocarcinoma; is: in situ. RCAS1 in gallbladder cancer 1927
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In conclusion, we have found that RCAS1 participates in
progression of GBC and that strong immunoreactivity for RCAS1
predicts a poor outcome. 
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